menadiol

Trade name: synkavite

Small moleculeapproved

Approved

Jun 1, 1941

Menadiol diphosphate is given as a vitamin K supplement to prevent bleeding caused by vitamin K deficiency. Vitamin K is normally obtained from the diet; for example it is found in green leafy vegetables, root vegetables, cereals and dairy products. Although it cannot be made by the human body itself, a certain amount of vitamin K is also made by bacteria that live in the gut. The body normally produces bile to help it absorb fats from the gut. In conditions where there is a problem with the production of bile, for example in certain liver diseases, or if there is a blockage of the bile duct, there can be problems absorbing fats. This can lead to vitamin K deficiency, decreased production of clotting factors and an increased risk of bleeding. In these situations, menadiol diphosphate is given as a vitamin K supplement to increase the production of clotting factors. It is water soluble so is readily absorbed from the gut. Also in 1974 was made attempt to develop tritiated derivatives of Synkavit (menadiol sodium diphosphate, MNDP) of high specific activity as a radioactive drug. Among the 203 evaluable treated cases, some form of response was observed in 23 out of 151 (15·2%) receiving the drug by intravenous injections and 13 out of 52 (25%) after intra-arterial injections. For the sites and types of malignant diseases which showed responses after either intravenous or intra-arterial administration among the 55 patients surviving at least 3 months after the first injection, some form of response was observed in 32 but only 5 of these showed either a "complete" or a "partial" response.It is concluded that further investigation is desirable. Kappadione is a Vitamin K derivative, was discontinued. It was manufactured by Eli Lilly and others Company. — NCATS

Clinical trial activity

5 trials · 15 clinical orgs · 2 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2008 (NCT00656786)

Timeline

1940s

  1. Jun 1, 1941

    Earliest FDA Approval

  2. Jan 6, 1942

    Roche — First NDA Organization

  3. Jan 6, 1942

    Roche — NDA Organization

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedJun 1, 1941

Chemistry & pharmacology

Loading structure…

SMILES

CC1=CC(O)=C2C=CC=CC2=C1O
Mol. weight
174.1959 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Discontinued

Oral

Yes

Parenteral

Yes

Topical

No

Sources

Also known as

  • 2-methyl-1,4-naphthalenedione
  • 2-methyl-1,4-naphthalenedione
  • 2-methyl-1,4-naphthalenedione
  • 2-methyl-1,4-naphthochinon
  • 2-methyl-1,4-naphthochinon
  • 2-methyl-1,4-naphthoquinone
  • 2-methyl-1,4-naphthoquinone
  • apatone
  • apatone
  • kappaxin
  • kappaxin
  • kappaxin
  • kayquinone
  • kayquinone
  • menadiol diphosphoric acid
  • menadiol diphosphoric acid
  • menadiol sulfate
  • menadion
  • menadione
  • menadione
  • menadione
  • menadione
  • menadione
  • menadione
  • menadione
  • menadione
  • menadione
  • menadione
  • menadione
  • menadione sodium bisulfite
  • menadione sodium bisulfite
  • menadione sodium bisulfite
  • menadione sodium bisulfite
  • menadione sodium bisulfite
  • menadione sodium bisulfite
  • menadione sodium hydrogen sulfite
  • menaphthene
  • menaphthene
  • menaphthon
  • menaphthone
  • menaphthone
  • menaphthone
  • menaphthone sodium bisulfite
  • menaphthone sodium bisulphite
  • sodium menadione bisulfite
  • vikasolum
  • vitamin k3
  • vitamin k3
  • vitamin k3
  • vitamin k 3
  • vitamin k 3
  • vitamin k3 sodium bisulfite

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03358706Phase 1Feb 2, 2018Johnson and Johnson
NCT04247087N/ASep 7, 2017Instituto Mexicano del Seguro Social, Universidad de Guanajuato
NCT01393821N/AJan 1, 2012Mayo Clinic
NCT01272830Phase 2Oct 1, 2010Crystal Clinic Orthopaedic Center LLC, IC-MedTech Corporation, Summa Health System
NCT00656786Phase 1Apr 1, 2008Harvard University, McGill University, Northwestern University, Solano Clinical Research, Spectrum Pharmaceuticals, Temple University, University of Texas at Houston, Washington University in St. Louis
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (15)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Crystal Clinic Orthopaedic Center LLCAcademic/Hospital1012010
Harvard UniversityAcademic/Hospital1012008
IC-MedTech CorporationFor profit1112010
Instituto Mexicano del Seguro SocialGovernment1112017
Johnson and JohnsonFor profit1112018
Mayo ClinicAcademic/Hospital1112012
McGill UniversityAcademic/Hospital1012008
Northwestern UniversityAcademic/Hospital1012008
Solano Clinical ResearchFor profit1012008
Spectrum PharmaceuticalsFor profit1112008
Summa Health SystemAcademic/Hospital1012010
Temple UniversityAcademic/Hospital1012008
Universidad de GuanajuatoAcademic/Hospital1012017
University of Texas at HoustonAcademic/Hospital1012008
Washington University in St. LouisAcademic/Hospital1012008
15 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
Eli LillyFor profitNDA2
RocheFor profitNDAJan 6, 1942